Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Needham Keeps 'Strong Buy' on Dendreon

Needham reiterated his strong buy rating for Dendreon (DNDN).

Analyst Mark Monane says data demonstrated Provenge's effect in the hardest-to-achieve clinical outcome (survival), and further validates the previous benefits seen with the vaccine in radiographic (time-to-disease progress), clinical (delay of bone pain onset), and immunological (T-cell proliferation) outcomes.

While Provenge (Phase 3, unpartnered) will likely not reach the market until the first quarter of 2006, he sees many events to stimulate investor interest over the next 6-to-12 months, including the completion of enrollment of another Provenge Phase 3 trial,and a marketing partnership for Provenge. He has a $15 12-month target.

blog comments powered by Disqus